Your patient comes into the ER with a head trauma. Another presents with an intracranial hemorrhage due to hypertension. What are the best ways to manage and treat ICH? You can find out in Pre-Conference Symposium I of the AHA/ASA’s International Stroke Conference 2018.
“Stroke in the Real World: There Will Be Blood: Management and Treatment of ICH,” held on Jan. 23 in Room 151 at the Los Angeles Convention Center, will include presentations on:
- Pre-hospital diagnosis and treatment
- Emergency department stabilization and triage of the ICH patient
- Understanding toxic clot constituents and cytotoxicity
- A debate on minimally invasive surgery
- How to investigate and image vascular lesions in ICH
- Effects of size and ICH expansion
- Amyloid angiopathy and microbleeds
Attendees also can participate in challenging breakout sessions and ask questions during an informal lunch with the faculty.
The symposium requires a separate fee to attend. Register now.
Symposium Schedule
9 a.m.
Welcome
Bruce Ovbiagele, MD, MSc, MAS, FAHA, Charleston, South Carolina
9:05 a.m.
“Scoop and Run: Pre-Hospital Diagnosis and Treatment of ICH”
Nerses Sanossian, MD, Los Angeles, California
9:20 a.m.
Q&A
9:30 a.m.
“The Golden Hour: ED Stabilization and Triage of the ICH Patient”
Opeolu Adeoye, MD, Cincinnati, Ohio
9:50 a.m.
Q&A
10 a.m.
“The Killing Fields: Toxic Clot Constituents and Cytotoxicity”
Guohua Xi, MD, Ann Arbor, Michigan
10:30 a.m.
Q&A
10:40 a.m.
“Double Indemnity: Surgery or Not? Minimally Invasive Surgery, Evidence and Debate” — Pro
Daniel F. Hanley, MD, FAHA, Baltimore, Maryland
10:55 a.m.
“Double Indemnity: Surgery or Not? Minimally Invasive Surgery, Evidence and Debate” — Con
Speaker TBD
11:10 a.m.
Q&A
11:20 a.m.
“Apocalypse Now: ICU Controversies: Where Is the Evidence?”
Navaz P. Karanjia, MD, San Diego, California
11:50 a.m.
Q&A
Noon-1 p.m.
Lunch
1 p.m.
“Lock, Stock and Two Barrels: Vascular Lesions in ICH? How to Investigate and Image”
Christian Stapf, MD, Montreal, Quebec, Canada
1:30 p.m.
Q&A
1:40 p.m.
“Larger Than Life: ICH Expansion and Size: Does the Size Matter?”
David Rodriguez-Luna, MD, PhD, Barcelona, Spain
2 p.m.
Q&A
2:10-2:55 p.m.
Concurrent IA (Room 502 A)
“The Ugly Truth: Practical Prognostication and Palliation: What Is the Evidence?”
Shouri Lahiri, MD, New York
Concurrent IB (Room 502 B)
“The Dark Knight: Complex Clinical Scenarios in ICH: When to Resume Anticoagulation”
Ashkan Shoamanesh, MD, Ancaster, Ontario, Canada
Concurrent IC (Room 515 A)
“Cloudy With a Chance of Meatballs: Role of Reversal Agents”
- Role of Reversal Agents — Pro
Patrick Lyden, MD, Los Angeles, California - Role of Reversal Agents — Con
Dariush Dowlatshahi, MD, PhD, FRCPC, Ottawa, Ontario, Canada
3-3:45 p.m.
Concurrent IIA (Room 502 A)
“The Ugly Truth: Practical Prognostication and Palliation: What Is the Evidence?”
Shouri Lahiri, MD, New York
Concurrent IIB (Room 502 B)
“The Dark Knight: Complex Clinical Scenarios in ICH: When to Resume Anticoagulation”
Ashkan Shoamanesh, MD, Ancaster, Ontario, Canada
Concurrent IIC (Room 515 A)
“Cloudy with a Chance of Meatballs: Role of Reversal Agents”
- Role of Reversal Agents — Pro
Patrick Lyden, MD, Los Angeles, California - Role of Reversal Agents — Con
Dariush Dowlatshahi, MD, PhD, FRCPC, Ottawa, Ontario, Canada
4 p.m.
“Gorillas in the Mist: Congophilic Amyloid Angiopathy and Microbleeds: Diagnosis, Prognosis and Implications for Treatment”
Branko N. Huisa, MD, San Diego, California
4:30 p.m.
Q&A
4:40 p.m.
“Kramer vs. Kramer Debate: ‘Sweet Spot’ for Blood Pressure after ICH” — Pro Intense Therapy
Craig Anderson, MD, PhD, Sydney NSW, Australia
4:50 p.m.
“Kramer vs. Kramer Debate: ‘Sweet Spot’ for Blood Pressure after ICH” — Pro Moderate Therapy
Ken S. Butcher, MD, PhD, FRCP(C), Parkville Melbourne, Australia
5 p.m.
Q&A
5:05 p.m.
Gone in 60 Seconds: Closing Remarks
Bruce Ovbiagele, MD, MSc, MAS, FAHA, Charleston, South Carolina